We are enabling deeper access to in vivo biology and driving durable and potentially transformational research on disease in a new era of advanced medicine. We believe our platform is the first to employ both proteomics, or the study of proteins and their functions, and single cell biology in an effort to fully characterize and link cellular […]

We will seek to identify, through the experience and expertise of our management team and board of directors, a biotech company that has demonstrated success and is primed to thrive in the rapidly evolving biotech industry. Our co-sponsor, Chardan Monterey, is affiliated with Chardan Capital Markets, LLC, or Chardan, an investment firm and a provider […]

We currently intend to concentrate our efforts in identifying high quality businesses that have recently undergone a restructuring. Our management team and Marblegate, an affiliate of our sponsor, have extensive experience investing in post-restructured companies. We believe that this experience makes us very well situated to identify, source, negotiate and execute a business combination at […]

We intend to focus on industries that complement our management team’s background, and to capitalize on the ability of our management team to identify and acquire a business, focusing on the healthcare and technology sectors, where our management team has extensive experience. Sectors we plan on exploring include, but are not limited to, technologically advanced […]

We are a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Our development programs are designed to address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. Resistance mutations limit the efficacy of existing targeted therapies by rendering […]

(Note: Life Time Group Holdings, Inc., sharply downsized its IPO at pricing on Oct. 6, 2021, to 39 million shares, down from 46.2 million shares, and priced the deal at $18 – the bottom of its $18-to-$21 price range – to raise $702 million. The IPO’s proceeds are far short of the projected proceeds of […]

We are focused on identifying a business combination target that provides transformational technology to experiential entertainment within the gaming, hospitality and entertainment industries that complements our board of directors and management team’s investing and operating expertise. Select industries include, but are not limited to, casino gaming, sports, sports betting and iGaming, distributed gaming, gaming technology […]

We intend to focus on high-growth U.S. and international acquisition targets in the FinTech and Embedded Finance sectors “Embedded Finance” refers to the combination of a non-financial service provider with a financial technology. Embedded Finance offers transformational opportunities among consumer or enterprise businesses that can rapidly monetize and scale through the integration of financial technology. There are […]

(Note: This is NOT an IPO. This is a NASDAQ uplift – a unit offering. Each unit consists of one share of common stock (proposed symbol GFAI) and one warrant to buy one share of common stock (proposed symbol GFAIW). The company’s stock has traded on the OTC Market under the symbol “GRDAF.” The shareholders approved […]

Note: This is a SPAC IPO of Class A ordinary shares. It is NOT a typical SPAC unit offering. We intend to focus our search for an initial business combination on technology-enabled companies operating in Latin America across a number of verticals, including, but not limited to, commerce, financial services, logistics, healthcare, education, enterprise software […]